Skip to main content

Advertisement

Table 2 Guidelines/local working group recommendations consulted for diagnosis of relapsed or refractory Ph(–) B-precursor ALL

From: Management and treatment of relapsed or refractory Ph(−) B-precursor ALL: a web-based, double-blind survey of EU clinicians

Guideline or local working group recommendation Number of respondents consulting for diagnosis, n (%)a
  France Germany Italy Spain UK Total
N = 15 N = 15 N = 15 N = 15 N = 15 N = 75
ASH/ASCO, US 6 (40) 2 (13) 10 (67) 5 (33) 3 (20) 26 (35)
EWALL, Europe 6 (40) 1 (7) 3 (20) 2 (13) 4 (27) 16 (21)
NCCN, US 3 (20)   7 (47) 4 (27)   14 (19)
GMALL, Germany 1 (7) 8 (53) 1 (7) 1 (7)   11 (15)
GIMEMA, Italy    10 (67)    10 (13)
PETHEMA, Spain     9 (60)   9 (12)
Othersb 3 (20)     1 (7) 4 (5)
  1. aRespondents could select multiple guidelines
  2. bThe following guidelines and/or local working group recommendations were consulted by one respondent for diagnosis: HAS, France; Onco LR, France; GELA, France; BCSH, UK
  3. ALL, acute lymphoblastic leukaemia; ASCO, American Society of Clinical Oncology; ASH, American Society of Hematology; BCSH, the British Committee for Standards in Haematology; EWALL, European Working group for Adult Lymphoblastic Leukemia; GELA, Groupe d’Etude des Lymphomes de l’Adulte (Study Group of the Adult Lymphoma); GIMEMA, Gruppo Italiano Malattie EMatologiche dell’Adultodell’Adulto (Italian Group for Haematological Diseases in Adults); GMALL, German Multicenter Study Group for Adult ALL; HAS, Haute Autorité de Santé (High Authority for Health); NCCN, the National Comprehensive Cancer Network; Onco LR, le réseau régional de Cancérologie en Languedoc Roussillon (regional network of Oncology in Languedoc Roussillon); PETHEMA, Program for Study and Treatment of Malignant Haemopathies, Spanish Society of Haematology